• Home  
  • Ozempic and Mounjaro may have a surprising effect on your brain
Ozempic and Mounjaro may have a surprising effect on your brain
- Science

Ozempic and Mounjaro may have a surprising effect on your brain

Popular medications used to treat obesity and type 2 diabetes, including semaglutide and tirzepatide, may have effects that extend beyond weight loss and blood sugar control. These drugs also influence biological processes involved in brain function, raising questions about whether they could help preserve memory and thinking abilities. To examine this possibility, researchers from the

Popular medications used to treat obesity and type 2 diabetes, including semaglutide and tirzepatide, may have effects that extend beyond weight loss and blood sugar control. These drugs also influence biological processes involved in brain function, raising questions about whether they could help preserve memory and thinking abilities.

To examine this possibility, researchers from the University of Gothenburg and the University of Copenhagen reviewed the existing scientific evidence at the invitation of the journal Science.

Studies involving animals suggest that GLP-1 medications can influence learning and memory. However, research involving humans has produced less consistent findings. Analyses of patient health records have found an association between GLP-1 treatment and a reduced risk of dementia among people with type 2 diabetes. These observational findings are encouraging, but they cannot determine whether the medications themselves are responsible for the lower risk.

More definitive results have also raised questions. In Novo Nordisk’s EVOKE and EVOKE+ clinical trials, semaglutide failed to slow the progression of early Alzheimer’s disease. Although the treatment affected several biological markers associated with Alzheimer’s, those changes did not translate into a measurable slowing of the disease.

Why Weight Loss Drugs May Still Benefit the Brain

Despite the disappointing Alzheimer’s results, researchers believe GLP-1 medications could still offer cognitive benefits to certain groups of patients.

People living with obesity or type 2 diabetes sometimes experience difficulties with attention, planning, and the speed at which they process information. These cognitive problems are often associated with metabolic health and blood vessel function, suggesting they may respond differently to treatment than the changes caused by Alzheimer’s disease.

Improving blood sugar regulation, metabolism, or vascular health could potentially help preserve cognitive abilities, even if the same medications cannot slow an established neurodegenerative disease.

Stina Börchers, the review’s first author and a researcher affiliated with both the University of Gothenburg and the University of Copenhagen, emphasizes the need to determine whether starting treatment earlier could make a difference.

“We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities, particularly if treatment begins before cognitive problems become established. It is also important to identify which patients might benefit,” says Stina Börchers.

Unlocking New Treatments to Protect Memory

A central unanswered question is how GLP-1 medications might influence the brain. Their potential cognitive effects could result from improvements in metabolic health, direct actions within the brain, or a combination of both.

Understanding these mechanisms could help researchers identify which patients are most likely to benefit and potentially lead to medications designed specifically to support memory and other thinking abilities.

Christoffer Clemmensen, the review’s senior author and a research group leader at the University of Copenhagen, sees an opportunity to use increasingly advanced obesity treatments to explore the connection between metabolism and the brain.

“Obesity medicines are becoming increasingly sophisticated, offering new opportunities to understand how metabolic regulation influences brain function. By disentangling the direct and indirect effects of these drugs on the brain, we may ultimately be able to develop treatments specifically aimed at preserving cognitive function,” says Christoffer Clemmensen.

The researchers are calling for clinical trials that evaluate memory, attention, and other cognitive abilities beginning when patients first start treatment. Following these changes over time could help establish whether GLP-1 drugs genuinely protect brain function and clarify who might benefit most.

They also stress that treatment is not without potential drawbacks, particularly for older adults and people who are physically frail. Rapid weight loss can lead to a reduction in muscle mass, which may weaken physical function and offset some of the possible benefits.

Careful monitoring will therefore be essential as researchers investigate whether today’s weight loss and diabetes medications could eventually provide new ways to protect the brain.

Source: www.sciencedaily.com

About Us

Toolq Media Is a Global News Platform Covering the Latest Developments and Breaking Stories from Around The World, Including World News, Business, Finance, Technology, Health, Politics, Science, Entertainment, Sports, and More.

Toolq

Toolq @2026. All Rights Reserved.